Regeneron Pharmaceuticals (REGN)
Health Care · Biopharmaceuticals
Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic areas.
What Regeneron Pharmaceuticals does
Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes medicines and biologics for patients with serious medical conditions. The company leverages proprietary technologies including human genetics and antibody platform to develop product candidates across multiple therapeutic areas. Regeneron works through collaborations and license agreements with companies including Sanofi and Bayer to advance its product pipeline and expand market reach. The company faces ongoing regulatory obligations, reimbursement pressures, and competition from biosimilar and alternative therapies.
Themes: ["biopharmaceuticals","monoclonal antibodies","drug pricing regulation","biosimilar competition","clinical development","human genetics","immunotherapy","government reimbursement"]
Fundamentals
- Price$667.95 as of 2026-07-09 close
- Market cap$69.9B as of 2026-07-10
- 1-year return+20.9% as of 2026-07-09 close
- P/E15.80 as of 2026-07-10
- Net margin+29.6% as of 2026-07-10
- Gross margin+85.7% as of 2026-07-10
- ROE+14.3% as of 2026-07-10
- Debt / equity0.09 as of 2026-07-10
- Revenue growth (YoY)+5.9% as of 2026-07-10
- Revenue CAGR (3y)+5.6% SEC XBRL
- Beta0.21 as of 2026-07-10
Dividend: yield +0.6%; pays a dividend.
Key risks (from latest filing)
["Competition from biosimilar products and alternative therapies that may be more cost-effective or superior, pressuring market share and pricing power","Regulatory delays or restrictions on product development and commercialization, including determinations by governmental authorities that could delay or restrict ability to continue development","Reimbursement uncertainty from third-party payors and government programs (Medicare, Medicaid), plus drug pricing regulation changes including April 2026 U.S. government pricing agreements that could impact revenue"]
Competitors & peers
- Amgen (AMGN)
- Celgene (CELG)
- Bristol Myers Squibb (BMY)
- Eli Lilly (LLY)
- Pfizer (PFE)
- Sanofi (SNYNF)
- Bayer
- Moderna (MRNA)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.